<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092521</url>
  </required_header>
  <id_info>
    <org_study_id>V501-013</org_study_id>
    <secondary_id>2004_081</secondary_id>
    <nct_id>NCT00092521</nct_id>
  </id_info>
  <brief_title>Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)</brief_title>
  <official_title>A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine if GARDASIL (V501) with four components is
      able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial
      Neoplasia (CIN)(Any Grade) and Adenocarcinoma In Situ (AIS), and genital warts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer</measure>
    <time_frame>Follow-up through end of study (4 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL) [Genital Warts, Vulvar/Vaginal Intraepithelial Neoplasia (Any Grade), Vulvar/Vaginal Cancer]</measure>
    <time_frame>Follow-up through end of study (4 years)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5759</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV 16 Monovalent Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V501</intervention_name>
    <description>Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Papillomavirus (HPV) 16 Monovalent</intervention_name>
    <description>HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female with an intact uterus with lifetime history of 0-4 sexual partners

        Exclusion Criteria:

          -  Prior Human Papillomavirus (HPV) vaccination

          -  Prior abnormal paps

          -  History of genital warts
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009 Mar 15;199(6):805-14. doi: 10.1086/597071.</citation>
    <PMID>19199546</PMID>
  </reference>
  <reference>
    <citation>Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.</citation>
    <PMID>18313445</PMID>
  </reference>
  <reference>
    <citation>Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10;356(19):1928-43.</citation>
    <PMID>17494926</PMID>
  </reference>
  <reference>
    <citation>Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007 May 19;369(9574):1693-702.</citation>
    <PMID>17512854</PMID>
  </reference>
  <reference>
    <citation>Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Value Health. 2008 Dec;11(7):1022-32. doi: 10.1111/j.1524-4733.2008.00342.x. Epub 2008 May 16.</citation>
    <PMID>18489503</PMID>
  </reference>
  <reference>
    <citation>Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8.</citation>
    <PMID>18000825</PMID>
  </reference>
  <reference>
    <citation>FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007 Nov 15;196(10):1438-46. Epub 2007 Oct 31.</citation>
    <PMID>18008221</PMID>
  </reference>
  <reference>
    <citation>Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 Jun 2;369(9576):1861-8.</citation>
    <PMID>17544766</PMID>
  </reference>
  <reference>
    <citation>Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007 Oct 15;196(8):1153-62. Epub 2007 Sep 17.</citation>
    <PMID>17955433</PMID>
  </reference>
  <reference>
    <citation>Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1777-84. doi: 10.1158/1055-9965.EPI-09-0067.</citation>
    <PMID>19505910</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2004</study_first_submitted>
  <study_first_submitted_qc>September 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2004</study_first_posted>
  <results_first_submitted>August 3, 2009</results_first_submitted>
  <results_first_submitted_qc>October 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2009</results_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study Protocol 013 (NCT00092521) (N =5759 total randomized) was comprised of two sub-studies: Protocol 011 (NCT00517309) (N=1877 total randomized) and Protocol 012 (NCT00092482) (N=3882 total randomized). Final safety data are presented in the results for Protocol 013 (NCT00092521): the final participant visit took place on 19 January 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent Human papillomavirus (HPV) vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Base Study Monovalent HPV (Type 16) Vaccine</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 2 Base Study Monovalent HPV (Type 16) Vaccine was not part of the pre-specified efficacy analysis population.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 - Base Study Placebo</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="P4">
          <title>Group 4 - Quadrivalent Human Papillomavirus Vaccine Extension</title>
          <description>This group includes subjects who entered the extension including subjects who in the base study received fewer than the full three doses of Quadrivalent HPV vaccine during the base study (i.e., subjects who received placebo in the base study; subjects who received monovalent [type 16] HPV vaccine in the base study, or subjects who received &lt;=2 doses of quadrivalent HPV vaccine in the base study). Subjects who discontinued the base portion of the study could enter the extension portion of the study. In the extension period subjects designated as &quot;Completed Period&quot; are those who received three doses of quadrivalent HPV vaccine and completed all required follow-up visits. Subjects designated as &quot;Not Completed&quot; are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vaccination (Day 1 Through Month 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2723"/>
                <participants group_id="P2" count="304"/>
                <participants group_id="P3" count="2732"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2583"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="2586"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized Not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unblinded</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New Medical History (Not AE)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up (After Month 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2599">Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up</participants>
                <participants group_id="P2" count="291">Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up</participants>
                <participants group_id="P3" count="2607">Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up</participants>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2353"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="1959"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="648"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects Continuing</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects in Extension</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="412"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visits Compressed</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study (Group 4)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="844"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="829"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received &gt;=1 Dose in Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="801"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="635"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="209"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Excluded ineligible for extension</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable/unwilling to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Base Study Monovalent HPV (Type 16) Vaccine</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 - Base Study Placebo</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2723"/>
            <count group_id="B2" value="304"/>
            <count group_id="B3" value="2732"/>
            <count group_id="B4" value="5759"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.2" spread="1.8"/>
                    <measurement group_id="B2" value="20.2" spread="1.74"/>
                    <measurement group_id="B3" value="20.3" spread="1.8"/>
                    <measurement group_id="B4" value="20.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="B2" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="B3" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="B4" value="20" lower_limit="16" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Although the upper age limit for this study was 23 years old, four subjects aged 24 were randomized into the study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>16 to 24 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2723"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="2732"/>
                    <measurement group_id="B4" value="5759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2723"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="2732"/>
                    <measurement group_id="B4" value="5759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="567"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="566"/>
                    <measurement group_id="B4" value="1226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1600"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="1558"/>
                    <measurement group_id="B4" value="3329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="266"/>
                    <measurement group_id="B4" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer</title>
        <time_frame>Follow-up through end of study (4 years)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and Polymerase Chain Reaction (PCR) negative to the relevant type through Month 7, and must provide follow-up data. Group 2 Base Study Monovalent HPV Vaccine was not part of the pre-specified efficacy analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 - Base Study Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and Polymerase Chain Reaction (PCR) negative to the relevant type through Month 7, and must provide follow-up data. Group 2 Base Study Monovalent HPV Vaccine was not part of the pre-specified efficacy analysis population.</population>
          <units>incidence rate per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2241"/>
                <count group_id="O2" value="2258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent relative risk reduction</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>95.1</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence Interval (CI) based on binomial tail probabilities and not from a dispersion parameter</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL) [Genital Warts, Vulvar/Vaginal Intraepithelial Neoplasia (Any Grade), Vulvar/Vaginal Cancer]</title>
        <time_frame>Follow-up through end of study (4 years)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide follow-up data.
Group 2 Base Study Monovalent HPV (Type 16) Vaccine was not part of the pre-specified efficacy analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Group 3 - Base Study Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL) [Genital Warts, Vulvar/Vaginal Intraepithelial Neoplasia (Any Grade), Vulvar/Vaginal Cancer]</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide follow-up data.
Group 2 Base Study Monovalent HPV (Type 16) Vaccine was not part of the pre-specified efficacy analysis population.</population>
          <units>incidence rate per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2261"/>
                <count group_id="O2" value="2279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent relative risk reduction</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>94.9</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>CI based on binomial tail probabilities and not from a dispersion parameter</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of subjects at risk included randomized subjects who had follow-up. For Group 4 (Extension), number of subjects at risk included those who received &gt;=1 vaccination in the extension study. Both serious and Other AEs were collected in the base period and only serious AEs were collected in the extension period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Base Study Monovalent HPV (Type 16) Vaccine</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="E3">
          <title>Group 3 - Base Study Placebo</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="E4">
          <title>Group 4 - Quadrivalent Human Papillomavirus Vaccine Extension</title>
          <description>This group includes subjects who entered the extension including subjects who in the base study received fewer than the full three doses of Quadrivalent HPV vaccine during the base study (i.e., subjects who received placebo in the base study; subjects who received monovalent [type 16] HPV vaccine in the base study, or subjects who received &lt;=2 doses of quadrivalent HPV vaccine in the base study). Subjects who discontinued the base portion of the study could enter the extension portion of the study. In the extension period subjects designated as &quot;Completed Period&quot; are those who received three doses of quadrivalent HPV vaccine and completed all required follow-up visits. Subjects designated as &quot;Not Completed&quot; are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to vaccine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Cervix dystocia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Failed induction of labor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Failed trial of labor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Fetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Fetal malposition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Premature labor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Prolonged labor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Transverse presentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix haemorrhage uterine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="801"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2458" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="2331" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="174" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="436" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="348" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="659" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="450" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site hypersensitivity</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2281" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="2014" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="694" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="413" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="802" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2673"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="2672"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

